SAN FRANCISCO, Jan. 6, 2016 /PRNewswire/ -- Nektar
Therapeutics' (Nasdaq: NKTR) President and Chief Executive Officer,
Howard W. Robin, is scheduled to
present at the upcoming 34th Annual J.P. Morgan Healthcare
Conference in San Francisco on
Tuesday, January 12, 2016 at
11:00 a.m. Pacific time.
The presentation will be accessible via a Webcast through a link
posted on the Investor Relations, Events Calendar section of the
Nektar website: http://www.nektar.com. In addition, the company
will webcast the Q&A breakout session immediately following its
presentation at 11:30 a.m. Pacific
Time. This Webcast will be available for replay until
February 19, 2016.
About Nektar
Nektar Therapeutics has a robust R&D pipeline in pain,
oncology, hemophilia and other therapeutic areas. In the area of
pain, Nektar has an exclusive worldwide license agreement
with AstraZeneca for MOVANTIK™ (naloxegol), the
first FDA-approved once-daily oral peripherally-acting
mu-opioid receptor antagonist (PAMORA) medication for the treatment
of opioid-induced constipation (OIC), in adult patients with
chronic, non-cancer pain. The product is also approved in
the European Union as MOVENTIG® (naloxegol) and is
indicated for adult patients with OIC who have had an inadequate
response to laxatives. The AstraZeneca agreement also includes
NKTR-119, an earlier stage development program that is a
co-formulation of MOVANTIK and an opioid. NKTR-181, a wholly-owned
mu-opioid analgesic molecule for chronic pain conditions, is in
Phase 3 development. In hemophilia, Nektar has a
collaboration agreement with Baxalta for ADYNOVATE™ [Antihemophilic
Factor (Recombinant)], a longer-acting PEGylated Factor VIII
therapeutic approved in the U.S. in patients over 12 with
hemophilia A. In anti-infectives, Amikacin Inhale is in Phase 3
studies conducted by Bayer Healthcare as an adjunctive
treatment for intubated and mechanically ventilated patients with
Gram-negative pneumonia.
Nektar's technology has enabled ten approved products in
the U.S. or Europe through partnerships with leading
biopharmaceutical companies, including AstraZeneca's MOVANTIK™,
Baxalta's ADYNOVATE™, UCB's Cimzia® for Crohn's disease and
rheumatoid arthritis, Roche's PEGASYS® for hepatitis C and Amgen's
Neulasta® for neutropenia.
Nektar is headquartered in San Francisco, California, with additional operations
in Huntsville, Alabama and Hyderabad, India. Further information about the company
and its drug development programs and capabilities may be found
online at http://www.nektar.com.
MOVANTIK™ is a trademark and MOVENTIG® is a registered trademark
of the AstraZeneca group of companies.
ADYNOVATE™ is a trademark of Baxalta Inc.
CONTACT: Jennifer Ruddock of Nektar Therapeutics,
+1-415-482-5585
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/nektar-therapeutics-president-and-ceo-howard-w-robin-to-present-at-the-34th-annual-jp-morgan-healthcare-conference-in-san-francisco-ca-300200531.html
SOURCE Nektar Therapeutics